FDA approves Dupixent as first biologic for children 2-11 with uncontrolled chronic spontaneous urticaria

Baird's international and global growth funds underperform MSCI benchmarks in Q2 2026.

In Q2 2026, Baird's Chautauqua International Growth Fund returned +10.39%, trailing the MSCI ACWI ex-U.S. Index's +14.49%. Key detractors included Alibaba and Lululemon, while Recruit and ASML contributed positively. The Global Growth Fund also lagge...